Skip to main navigation
Skip to search
Skip to main content
Prinses Máxima Centrum Home
Nederlands
English
Search content at Prinses Máxima Centrum
Home
Profiles
Research Groups
Equipment
Research output
Prizes
Activities
Press/Media
Direct targeted therapy for MLL-fusion-driven high-risk acute leukaemias
Sandra Cantilena
, Luca Gasparoli
, Deepali Pal
,
Olaf Heidenreich
, Jan-Henning Klusmann
, Joost H A Martens
, Alexandre Faille
, Alan J Warren
, Mawar Karsa
, Ruby Pandher
, Klaartje Somers
, Owen Williams
, Jasper de Boer
Research output
:
Contribution to journal
›
Article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Direct targeted therapy for MLL-fusion-driven high-risk acute leukaemias'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Targeted Therapy
100%
MLL Fusions
100%
MLL Fusion Proteins
100%
High-risk Acute Leukemia
100%
Fusion-driven
100%
Disulfiram
57%
Fusion Oncoprotein
28%
Drug-induced
28%
Colony Formation
28%
Unmet Medical Need
14%
Pediatric Cancer
14%
RNA Sequencing (RNA-seq)
14%
Transcription Factor
14%
Therapeutic Potential
14%
Poor Prognosis
14%
Cell Proliferation
14%
Reporter-based
14%
Drug Screening
14%
Epigenetic Modification
14%
Apoptosis Assay
14%
Direct Targeting
14%
Oncoprotein
14%
Infant Leukemia
14%
Protein Binding
14%
Fusion Inhibition
14%
Leukemia Progression
14%
Western Blot
14%
In Vivo Assay
14%
Efficient Ablation
14%
KMT2A
14%
Antitumor Activity
14%
ChIP-seq Analysis
14%
ChIP-qPCR
14%
Statistical Test
14%
Luciferase Reporter
14%
Induced Differentiation
14%
Quantitative PCR
14%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Leukemia
100%
Chimeric Protein
100%
Disulfiram
57%
Oncoprotein
42%
Leukemia
28%
Malignant Neoplasm
14%
Drug Screening
14%
Disease
14%
Antitumor Activity
14%
Western Blot
14%
Protein Binding
14%
Lead Compound
14%
Transcription Factors
14%
Luciferase
14%
Apoptosis Assay
14%
Medicine and Dentistry
Western Blotting
14%